- Orion selects lead antibodies from the second discovery program
- Collaboration aims to discover and develop new bispecific antibody cancer therapeutics leveraging Alligator’s technologies and RUBY® bispecific format
- Option exercise triggers milestone payment to Alligator
"Our research collaboration with Alligator has allowed us to identify again new lead molecules with potential to be selected for clinical development. It is fantastic to see how productive this collaboration is," said Outi Vaarala, Senior Vice President, Innovative Medicines Business and R&D,Orion Corporation
"The collaboration with Orion that was initiated less than 3 years ago continues to be very productive with Alligator delivering two clinical candidates to date. With this option exercise, we believe Orion has selected considerably differentiated bispecific antibodies that could lead to highly innovative treatments." said Søren Bregenholt, CEO ofAlligator Bioscience . "We look forward to continuing to work alongside Orion, helping them move these drug candidates to the clinic as quickly as possible."
Under the initial agreement signed in
© Modular Finance, source